File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Twelve-year follow-up of a prospective randomized trial of hepatitis B recombinant DNA yeast vaccine versus plasma-derived vaccine without booster doses in children

TitleTwelve-year follow-up of a prospective randomized trial of hepatitis B recombinant DNA yeast vaccine versus plasma-derived vaccine without booster doses in children
Authors
Issue Date1999
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/
Citation
Hepatology, 1999, v. 29 n. 3, p. 924-927 How to Cite?
AbstractA total of 318 children were prospectively randomized in group 1 with two 5-μg doses of recombinant vaccine given at 0 and 1 month; in group 2 with three 5-μg doses of recombinant vaccine given at 0, 1, and 6 months; or in group 3 with three doses of plasma-derived vaccine given at 0, 1, and 6 months. Eleven subjects with a hepatitis B surface antigen antibody (anti- HBs) titer of less than 10 mIU/mL at 12 months were given an extra dose of vaccine and were excluded from analysis. No booster doses were given to any other subjects. All children were followed up yearly for the level of anti- HBs titers and for the detection of hepatitis B infection. At the 12th year of follow-up, there were significantly fewer subjects with anti-HBs of 10 mIU/mL or above in group 1 (60.4%) when compared with group 2 (81.4%; P = .0287) and group 3 (79.0%; P = .0381). The geometric mean titers (GMTs) of subjects of group 1 were significantly lower than those of group 2 and group 3 throughout the 12 years of follow-up. A total of 65 subjects had one or more episodes of anamnestic response. No subject became positive for hepatitis B surface antigen (HBsAg); 2 became positive for hepatitis B core antigen antibody (anti-HBc). In conclusion, the long-term protective immunity was better with three doses of hepatitis B vaccine (either the recombinant or plasma-derived) than with two doses. However, protection from hepatitis B infection could be equally achieved by either two doses or three doses of the vaccine. Booster doses were not necessary, probably because of effective anamnestic response.
Persistent Identifierhttp://hdl.handle.net/10722/78123
ISSN
2015 Impact Factor: 11.711
2015 SCImago Journal Rankings: 4.752
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorYuen, MFen_HK
dc.contributor.authorLim, WLen_HK
dc.contributor.authorCheng, CCen_HK
dc.contributor.authorLam, SKen_HK
dc.contributor.authorLai, CLen_HK
dc.date.accessioned2010-09-06T07:39:24Z-
dc.date.available2010-09-06T07:39:24Z-
dc.date.issued1999en_HK
dc.identifier.citationHepatology, 1999, v. 29 n. 3, p. 924-927en_HK
dc.identifier.issn0270-9139en_HK
dc.identifier.urihttp://hdl.handle.net/10722/78123-
dc.description.abstractA total of 318 children were prospectively randomized in group 1 with two 5-μg doses of recombinant vaccine given at 0 and 1 month; in group 2 with three 5-μg doses of recombinant vaccine given at 0, 1, and 6 months; or in group 3 with three doses of plasma-derived vaccine given at 0, 1, and 6 months. Eleven subjects with a hepatitis B surface antigen antibody (anti- HBs) titer of less than 10 mIU/mL at 12 months were given an extra dose of vaccine and were excluded from analysis. No booster doses were given to any other subjects. All children were followed up yearly for the level of anti- HBs titers and for the detection of hepatitis B infection. At the 12th year of follow-up, there were significantly fewer subjects with anti-HBs of 10 mIU/mL or above in group 1 (60.4%) when compared with group 2 (81.4%; P = .0287) and group 3 (79.0%; P = .0381). The geometric mean titers (GMTs) of subjects of group 1 were significantly lower than those of group 2 and group 3 throughout the 12 years of follow-up. A total of 65 subjects had one or more episodes of anamnestic response. No subject became positive for hepatitis B surface antigen (HBsAg); 2 became positive for hepatitis B core antigen antibody (anti-HBc). In conclusion, the long-term protective immunity was better with three doses of hepatitis B vaccine (either the recombinant or plasma-derived) than with two doses. However, protection from hepatitis B infection could be equally achieved by either two doses or three doses of the vaccine. Booster doses were not necessary, probably because of effective anamnestic response.en_HK
dc.languageengen_HK
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/en_HK
dc.relation.ispartofHepatologyen_HK
dc.rightsHepatology. Copyright © John Wiley & Sons, Inc.en_HK
dc.subject.meshChilden_HK
dc.subject.meshChild, Preschoolen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshFollow-Up Studiesen_HK
dc.subject.meshHepatitis B - prevention & controlen_HK
dc.subject.meshHepatitis B Antibodies - analysisen_HK
dc.subject.meshHepatitis B Core Antigens - immunologyen_HK
dc.subject.meshHepatitis B Surface Antigens - analysisen_HK
dc.subject.meshHepatitis B Vaccines - administration & dosage - therapeutic useen_HK
dc.subject.meshHumansen_HK
dc.subject.meshImmunization, Secondaryen_HK
dc.subject.meshInfanten_HK
dc.subject.meshLongitudinal Studiesen_HK
dc.subject.meshMaleen_HK
dc.subject.meshPlasmaen_HK
dc.subject.meshProspective Studiesen_HK
dc.subject.meshVaccines, DNA - administration & dosage - therapeutic useen_HK
dc.subject.meshYeastsen_HK
dc.titleTwelve-year follow-up of a prospective randomized trial of hepatitis B recombinant DNA yeast vaccine versus plasma-derived vaccine without booster doses in childrenen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0270-9139&volume=29&issue=3&spage=924&epage=927&date=1999&atitle=Twelve-Year+Follow-up+of+a+Prospective+randomized+trial+of+hepatitis+B+recombinant+DNA+yeast+vaccine+versus+plasma-derived+vaccine+without+booster+doses+in+childrenen_HK
dc.identifier.emailYuen, MF:mfyuen@hkucc.hku.hken_HK
dc.identifier.emailLai, CL:hrmelcl@hku.hken_HK
dc.identifier.authorityYuen, MF=rp00479en_HK
dc.identifier.authorityLai, CL=rp00314en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.pmid10051499-
dc.identifier.scopuseid_2-s2.0-0033020623en_HK
dc.identifier.hkuros40863en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0033020623&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume29en_HK
dc.identifier.issue3en_HK
dc.identifier.spage924en_HK
dc.identifier.epage927en_HK
dc.identifier.isiWOS:000078911700042-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridYuen, MF=7102031955en_HK
dc.identifier.scopusauthoridLim, WL=24492170000en_HK
dc.identifier.scopusauthoridCheng, CC=7404796652en_HK
dc.identifier.scopusauthoridLam, SK=21534605100en_HK
dc.identifier.scopusauthoridLai, CL=7403086396en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats